R&D phase is ongoing!

We are working on creating ERBIOSYS Precision Oncology Platform.

The platform will:

Use patient’s multiomic molecular information extracted from tumor tissue - mutations on different levels: DNA, RNA, methylation, protein levels, phosphorylation, and other biomarkers associated with breast cancer occurrence, development, treatment and resistance to treatment;

Use patient’s cancer treatment and other medical history;

Create tumor profile by analyzing cancer signaling pathways;

Generate a report with recommended (including conventional therapies, and unconventional drugs and supplements) and ineffective therapies, based on NCCN guidelines, precision oncology recommendations, PubMed and other medical publications;

Provide explanations of how each of the suggested therapies work (mechanism of action) and links to PubMed or other publications justifying the suggestions.

For now we can guide you to better understand your case.

Our scientists can help you and your oncologist to:

investigate your particular breast cancer case;

get a deeper understanding of the molecular biology of your cancer;

take advantage of precision oncology.